Physician profile
Kyle Weaver
NPI 1609141233
$1,589.94
in general payments reported to CMS, 2019-2025
11 companies · $238 in 2025
The $238 reported for 2025 was more than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $176 · 2020: $42.25 · 2021: $355 · 2022: $153 · 2023: $315 · 2024: $310 · 2025: $238.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $863.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $863.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Vision Care, INC. | $381.14 | 2019-2025 | Acuvue |
| Coopervision INC. | $260.95 | 2022-2024 | Myday Contact Lens, Clariti Contact Lens |
| Alcon Vision LLC | $229.76 | 2019-2025 | Total30, Precision 1 |
| Bausch & Lomb Americas INC. | $213.32 | 2023-2025 | Infuse |
| Biotissue Holdings INC. | $171.65 | 2021 | |
| Allergan, INC. | $130.78 | 2021 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $59.26 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $56.75 | 2020-2022 | |
| Shire North American Group INC | $37.89 | 2019 | |
| Omeros Corporation | $34.08 | 2019 | |
| Aerie Pharmaceuticals, INC. | $14.36 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kyle Weaver listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.